- Conditions
- Renal Transplant Failure and Rejection
- Interventions
- Siplizumab, Rabbit anti-thymocyte globulin
- Drug
- Lead sponsor
- Nefro Avillion Clinical Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Sacramento, California • Tampa, Florida • Atlanta, Georgia + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 307
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplantation
- Interventions
- Rabbit Antithymocyte Globulin, Velcade, Rituxan
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Hematologic Malignancies
- Interventions
- Cloretazine, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Chronic Myelogenous Leukemia
- Interventions
- Fludarabine, Busulfan, NK cell infusion:, Interleukin-2, Anti-Thymocyte Globulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Methotrexate, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Haploidentical Bone Marrow Transplantation, Hydroxyurea, Rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, Mesna
- Procedure · Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 5 Years to 45 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 24 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Preparative Regimen, NK Cells, Interleukin-2, CD34 Graft/Anti-thymocyte globulin, Donor TCR α/β-depleted Graft/ATG
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Lymphoma, Disorder Related to Bone Marrow Transplantation
- Interventions
- Fludarabine, Melphalan, Allogeneic Transplant, Thymoglobulin
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Aplastic Anemia, Bone Marrow Failure Syndromes
- Interventions
- Bone marrow transplant, Thymoglobulin, Fludarabine, Cyclophosphamide, TBI, Mesna, Tacrolimus, Mycophenolic acid mofetil
- Procedure · Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 73 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Milwaukee, Wisconsin
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Lenalidomide, Fludarabine, Rituximab, Thymoglobulin, Stem Cell Transplantation, Bendamustine, Allopurinol
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Sickle Cell Disease, Thalassemia, Beta, Thalassemia
- Interventions
- Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Interventions
- Mylotarg, Fludarabine, Melphalan, Anti-thymocyte globulin, Stem cell transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Interventions
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine, Alemtuzumab
- Biological · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute (Cellular) Renal Allograft Rejection
- Interventions
- rATG
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Aplastic Anemia
- Interventions
- cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
- Drug · Procedure · Radiation
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
- Biological · Drug · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
- Interventions
- Thymoglobulin, Bortezomib, Tacrolimus
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide, Busulfan, Fludarabine, Melphalan, Clofarabine, HPC(A) stem cell allograft, Rituximab, Rabbit antithymocyte globulin
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Transplantation
- Interventions
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 14 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- anti-thymocyte globulin, melphalan
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- EWINGS SARCOMA
- Interventions
- Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky